OpenAI Launches GPT Targeting Longevity Research
Published 10 February 2025
American tech company OpenAI has partnered with biotech research firm Retro (also US-based) to launch a generative artificial intelligence (AI) model that can support longevity research. While the model isn’t commercially available, it demonstrates ongoing interest in deploying tech to help humans live longer – a phenomenon we detail in Longevity: The Tech-Lengthened Lifespan.
This new language model can devise novel proteins capable of turning regular human cells into stem cells (cells that are able to transform into any body part). The model builds off Retro’s research into Yamanaka factors. Yamanaka factors are proteins that enable mature human cells to regain the properties of stem cells. Researchers could use OpenAI’s new language model to engineer Yamanaka factors to accelerate the process of shifting mature cells into stem cells (it currently takes several weeks). The goal is to enable a future in which scientists can build replacement organs for patients, among other use cases.
It’s a busy time for longevity businesses. By 2031, longevity therapies are expected to be a $4.1bn global market, up from $2.7bn in 2023 (InsightAce Analytic, 2024). However, as we explain in 10 Wellness Trends to Watch 2025, most products currently on the market are preventative supplements rather than medical therapies.
This is starting to change. The partnership between OpenAI and Retro is one of many bringing AI to longevity research. In December 2024, Dublin-based biotech company Nuritas received $42m in funding for its AI model that can uncover new peptides (chains of amino acids that are believed to support healthy cell function). In January 2025, American venture capital firm Andreessen Horowitz partnered with US-based drug manufacturer Eli Lilly to launch a biotech fund intended to support companies deploying AI for health outcomes, including improving longevity.
For more, see Medtech: AI-Driven Smart Health Solutions.
